Global Postmenopausal Vaginal Atrophy Treatment Market Data Survey Report 2025 [Report Updated: 20102017] Prices from USD $1500
Summary
Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.
The global Postmenopausal Vaginal Atrophy Treatment market will reach Volume Million USD in 2017 with CAGR xx% 20182025. The main contents of the report including:
Global market size and forecast
Regional market size, production data and export import
Key manufacturers manufacturing sites, capacity and production, product specifications etc.
Average market price by SUK
Major applications
Key manufacturers are included based on manufacturing sites, capacity and production, product specifications etc.:
Allergan
Pfizer
Shionogi
Novo Nordisk
Teva Pharmaceutical
Bayer.
Major applications as follows:
Topical Estrogen
Systemic Estrogen
Nonhormonal Therapy
Regional market size, production data and export import:
AsiaPacific
North America
Europe
South America
Middle East Africa
Original Article: Global Postmenopausal Vaginal Atrophy Treatment Market Data Survey Report 2025 [Report Updated: 20102017] Prices from USD $1500
